review article | Q7318358 |
scholarly article | Q13442814 |
P50 | author | Gaia Peluso | Q89800694 |
Gianluca Minieri | Q114536993 | ||
Concetta Anna Dodaro | Q114536994 | ||
Massimiliano Creta | Q56849247 | ||
Nicola Carlomagno | Q59656795 | ||
Armando Calogero | Q85237107 | ||
Silvia Angeletti | Q87834640 | ||
Paola Incollingo | Q89800691 | ||
Massimo Ciccozzi | Q28743803 | ||
Caterina Sagnelli | Q42257713 | ||
Evangelista Sagnelli | Q41549310 | ||
P2093 | author name string | Maria Candida | |
P2860 | cites work | An update on the treatment options for HBV/HCV coinfection | Q47586705 |
Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy | Q49712889 | ||
Malfunctions of robotic system in surgery: role and responsibility of surgeon in legal point of view. | Q50867414 | ||
Informed consent in robotic surgery: quality of information and patient perception. | Q53736466 | ||
Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. | Q54261696 | ||
Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma | Q57491234 | ||
EASL Recommendations on Treatment of Hepatitis C 2015 | Q58324800 | ||
Direct-acting antivirals and hepatitis B virus (HBV) reactivation in co-infected HBV/HCV kidney-transplant recipients | Q59350534 | ||
Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia | Q59356129 | ||
Suboptimal kidney: the experience of a single transplant unit | Q79996734 | ||
Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation | Q80572083 | ||
The finding of vascular and urinary anomalies in the harvested kidney for transplantation | Q80783151 | ||
Healing of surgical incision in kidney transplantation: a single transplant center's experience | Q83937496 | ||
Kidney | Q87056246 | ||
New food approaches to reduce and/or eliminate increased gastric acidity related to gastroesophageal pathologies | Q88577052 | ||
Interventions for dialysis patients with hepatitis C virus (HCV) infection | Q24187826 | ||
Lactoferrin Adsorbed onto Biomimetic Hydroxyapatite Nanocrystals Controlling - In Vivo - the Helicobacter pylori Infection | Q27335157 | ||
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 | ||
Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey | Q31107505 | ||
Serum alanine aminotransferase in hepatitis c screening of patients on hemodialysis | Q31827501 | ||
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial | Q33167896 | ||
Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy | Q33395896 | ||
Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group | Q33464499 | ||
Hepatitis C virus infection and dialysis: 2012 update | Q33710828 | ||
Hepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection | Q33735206 | ||
Rare multiple primary malignancies among surgical patients-a single surgical unit experience | Q33768627 | ||
Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report. | Q34465551 | ||
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women | Q34589830 | ||
Effect of kidney transplantation on outcomes among patients with hepatitis C | Q35012447 | ||
Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors | Q35146790 | ||
Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans | Q35528192 | ||
Management of telaprevir-based triple therapy for hepatitis C virus recurrence post liver transplant | Q35626794 | ||
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study | Q35818080 | ||
Epidemiology and clinical significance of hepatotropic infections in dialysis patients. Recent evidence | Q35910416 | ||
Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection | Q36077546 | ||
Difficult vascular conditions in kidney transplantation | Q36498706 | ||
Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant | Q36622506 | ||
Primary extraosseous Ewing sarcoma of the lung in children | Q36791086 | ||
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. | Q36870864 | ||
The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment | Q36910603 | ||
Hepatitis C virus and kidney disease | Q37229019 | ||
Complicated diverticulitis in kidney transplanted patients: analysis of 717 cases | Q41731026 | ||
Prevention of fluid effusion in kidney transplantation with the use of hemostatic biomaterials | Q41731042 | ||
Total colectomy for cancer: analysis of factors linked to patients' age. | Q41757591 | ||
EASL recommendations on treatment of hepatitis C 2014. | Q42219300 | ||
Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients | Q42222997 | ||
Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection | Q42255783 | ||
Benefits associated with antiviral treatment in kidney allograft recipients with chronic hepatitis B virus infection. | Q42978334 | ||
Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient. | Q42994735 | ||
Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. | Q42995926 | ||
Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients | Q43000880 | ||
Kidney transplantation from a donor who is HCV antibody positive and HCV-RNA negative | Q43001383 | ||
Impact of immunosuppressive therapy on hepatitis C infection after renal transplantation. | Q43032343 | ||
Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients | Q43038211 | ||
Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis | Q43039778 | ||
Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients | Q43040103 | ||
Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus | Q43964552 | ||
Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand | Q44177155 | ||
Impact of hepatitis B and C virus on kidney transplantation outcome | Q44231771 | ||
Older kidneys donor transplantation: five years' experience without biopsy and using clinical laboratory and macroscopic anatomy evaluation. | Q44367232 | ||
Sex difference in the interaction of alcohol intake, hepatitis B virus, and hepatitis C virus on the risk of cirrhosis | Q45324819 | ||
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study | Q45356128 | ||
Association of hepatitis C virus infection with risk of ESRD: a population-based study | Q45357852 | ||
Hepatitis C virus infection and de novo glomerular lesions in renal allografts | Q45731872 | ||
Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. | Q45967412 | ||
Wound complications after kidney transplantation in nondiabetic patients. | Q46001916 | ||
Treatment of Hepatitis C Infection in Renal Transplant Recipients: The Long Wait Is Over | Q46080993 | ||
Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation | Q46831252 | ||
Gender differences in chronic liver diseases in two cohorts of 2001 and 2014 in Italy | Q47573260 | ||
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005 | Q37268370 | ||
Hepatitis C therapy before and after liver transplantation | Q37282557 | ||
Early Results of Pilot Study Using Hepatitis C Virus (HCV) Positive Kidneys to Transplant HCV Infected Patients with End-Stage Renal Disease Allowing for Successful Interferon-Free Direct Acting Antiviral Therapy after Transplantation | Q37527974 | ||
Hepatitis C virus and nonliver solid organ transplantation. | Q38061560 | ||
The rapid evolution of treatment strategies for hepatitis C. | Q38204657 | ||
Dendritic cell-based vaccines: clinical applications in breast cancer. | Q38206821 | ||
Perioperative care of elderly outpatient: a review | Q38246630 | ||
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment | Q38286904 | ||
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? | Q38559952 | ||
Etiological factors of chronic hepatitis in Italy: a 2014 national survey | Q38679799 | ||
What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. | Q38680812 | ||
HCV and the kidney | Q38685571 | ||
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled | Q38747790 | ||
The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. | Q38757351 | ||
Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals | Q38779980 | ||
Hepatitis C Virus Infection in Chronic Kidney Disease | Q38812607 | ||
Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. | Q38971057 | ||
Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. | Q39049269 | ||
Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents | Q39051675 | ||
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories | Q39096731 | ||
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients | Q39519539 | ||
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease | Q39920614 | ||
Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study | Q40107697 | ||
Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfected patients | Q40113130 | ||
Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents | Q40278284 | ||
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. | Q40278746 | ||
Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. | Q40297644 | ||
Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min | Q40303431 | ||
TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. | Q40482870 | ||
Use of HCV+ Donors Does Not Affect HCV Clearance With Directly Acting Antiviral Therapy But Shortens the Wait Time to Kidney Transplantation | Q40586756 | ||
Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents | Q40620558 | ||
Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. | Q40774514 | ||
Impact of PNPLA3 variants on liver histology of 168 patients with HIV infection and chronic hepatitis C. | Q40819897 | ||
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study | Q40957442 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | kidney transplantation | Q740909 |
eradication of infectious diseases | Q1347969 | ||
Hepacivirus | Q2082778 | ||
chronic hepatitis C | Q55779873 | ||
transplant recipient | Q58659328 | ||
sustained virologic response | Q70490546 | ||
antiviral agent | Q40207875 | ||
P304 | page(s) | 4674560 | |
P577 | publication date | 2019-04-07 | |
P1433 | published in | BioMed Research International | Q17509958 |
P1476 | title | Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients | |
P478 | volume | 2019 |
Q92716402 | Colorectal Cancer in the Elderly Patient: The Role of Neo-adjuvant Therapy |
Q92544060 | Differential Diagnosis: Retroperitoneal Fibrosis and Oncological Diseases |
Q92410137 | Erratum to "Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients" |
Q90567346 | Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota |
Q92154701 | Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention |